Review: hepatitis B immune globulin for prevention of hepatitis B infection.
Specific hepatitis B immune globulin (HBIG) contains a high titer of antibody to hepatitis B surface antigens and provides immediate passive protection against infection with hepatitis B virus, after acute exposure to infection. It is now generally combined with active immunization with hepatitis B vaccine. The principal indications for administration of HBIG are: a single acute percutaneous exposure to hepatitis B virus (HBV); mucocutaneous exposure; unprotected sexual exposure; mother-to-infant transmission; prevention of re-infection after liver transplantation; non-responders to hepatitis B vaccine and immunosuppressed patients.
Zuckerman
J N
JN
Academic Centre for Travel Medicine and Vaccines, WHO Collaborating Centre for Reference, Research and Training in Travel Medicine, Royal Free & University College Medical School, University College London, UK. j.zuckerman@medsch.ucl.ac.uk
D005260:Female; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control* / Q000635:transmission; D006510:Hepatitis B Antibodies / Q000008:administration & dosage*; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000008:administration & dosage*; D018445:Infectious Disease Transmission, Vertical; D016031:Liver Transplantation; D016602:Needlestick Injuries; D011247:Pregnancy; D012008:Recurrence; D012725:Sexual Behavior
D006510:Hepatitis B Antibodies; D007136:Immunoglobulins